Why Exelixis, Inc. Rose Higher Today
Exelixis (NASDAQ: EXEL) is up 24% at 12:21 p.m. EDT after announcing that the phase 3 Celestial trial met its primary endpoint of helping liver cancer patients taking Cabometyx live longer than those taking placebo.
Separately, the biotech also said the Food and Drug Administration accepted its marketing application to expand Cabometyx's label to first-line kidney cancer and gave the application a priority review with a goal of completing the review by Feb. 15, 2018. That's good progress, but widely expected, so most of today's jump is due to the Celestial result.
Image source: Getty Images.
Source: Fool.com
Exelixis Inc. Stock
€46.00
1.520%
With 18 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
On the other hand, the target price of 43 € is below the current price of 46.0 € for Exelixis Inc., so the potential is actually -6.52%.
